Myriad's Flurizan fails Phase II

MYGN said its Flurizan (MPC-7869) missed the three primary endpoints in a Phase II trial to treat mild to moderate Alzheimer's disease (AD). The 12-month, double-blind, placebo-controlled U.K. and Canadian trial in 207 patients was measuring Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), Clinical Dementia Rating-Sum of Boxes (CDR-sb) and ADAS-cog. ...